Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11926-009-0033-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and Evaluation of the Dermatomyositis Outcomes for Muscle and Skin as an Outcome Measure in Dermatomyositis Clinical Trials.
JID Innov
March 2025
Corporal Micheal J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
The Total Improvement Score (TIS), which is used as the primary efficacy measure in dermatomyositis (DM) clinical trials, lacks a skin-specific measure. However, skin is a defining feature of DM. In this study, data were analyzed from the phase 3 trial of lenabasum in DM.
View Article and Find Full Text PDFClinicopathological Features of Mixed Connective Tissue Disease-Related Myositis: A Case Series.
Muscle Nerve
January 2025
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Introduction: Mixed connective tissue disease (MCTD) patients often have myositis, however, myopathological and clinical data for MCTD are limited. Recent reports have shown that the pathology of MCTD myositis resembles that of immune-mediated necrotizing myopathy (IMNM), whereas earlier reports described perifascicular atrophy or inflammatory infiltrates predominantly in the perivascular region in MCTD myositis. We aim to describe the clinical and myopathological features of MCTD myositis.
View Article and Find Full Text PDFTofacitinib Treatment for Active Dermatomyositis and Anti-synthetase Syndrome: A Prospective Cohort Pilot Study.
Rheumatology (Oxford)
January 2025
Department of Rheumatology and Immunology and Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People's Hospital, Beijing, 100044, China.
Objectives: The objective of this study was to evaluate the efficacy and safety of tofacitinib in the treatment of active dermatomyositis (DM) and anti-synthetase syndrome (ASS).
Methods: Tofacitinib was administered at a dose of 5 mg twice daily to patients who exhibited inadequate response to conventional treatments. The primary end point was the reduction of T follicular helper (Tfh) cells at week 24.
Exploring the clinical profiles and management of juvenile dermatomyositis in Africa: a survey of African rheumatology care providers.
Pediatr Rheumatol Online J
January 2025
Aga Khan University Medical College East Africa, Nairobi, Kenya.
Background: There are limited studies of juvenile dermatomyositis (JDM) in low and middle-income countries (LMIC). Many demonstrate delays to care, high prevalence of severe manifestations, and high mortality. Given the disease-associated damage with JDM, understanding JDM in Africa further is critical.
View Article and Find Full Text PDFAcquired leukonychia with lichenoid papules.
JAAD Case Rep
February 2025
Forefront Dermatology, Noblesville, Indiana.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!